Repligen posts investor presentation outlining bioprocessing growth strategy, margin expansion path

Repligen

Repligen

RGEN

0.00
  • Repligen outlined a strategy to outpace bioprocessing market growth, targeting a doubling of the business from 2025 to 2030.
  • FY25 revenue totaled USD 738 million; revenue grew at an 18% CAGR from 2019 to 2025.
  • Management reiterated a path to about 30% EBITDA margin, balancing cost actions with investment to support longer-term growth.
  • FY26 outlook calls for growth led by Analytics and Chromatography at more than 20% each; Filtration at roughly mid-single digits.
  • Capital equipment funnel was up more than 20% year over year from May 2025 to May 2026, supporting low double-digit equipment growth assumptions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Repligen Corporation published the original content used to generate this news brief on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.